These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11119139)

  • 1. Microinvasive lobular carcinoma of the breast.
    Howat AJ; Armour A; Ellis IO
    Histopathology; 2000 Nov; 37(5):477-8. PubMed ID: 11119139
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lobular carcinoma-in-situ and ductal hyperplasia of breast].
    Fu L
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):4-7. PubMed ID: 16608640
    [No Abstract]   [Full Text] [Related]  

  • 3. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
    Calzada L; Salazar EL; Pedron Nuevo N
    Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lobular carcinoma in situ with microinvasion.
    Nemoto T; Castillo N; Tsukada Y; Koul A; Eckhert KH; Bauer RL
    J Surg Oncol; 1998 Jan; 67(1):41-6. PubMed ID: 9457256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study.
    Esposito NN; Chivukula M; Dabbs DJ
    Mod Pathol; 2007 Jan; 20(1):130-8. PubMed ID: 17143261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign proliferative lesions and in situ carcinoma of the breast: new immunohistological findings and their biological implications.
    Böcker W; Bier B; Ludwig A; de Hesselle B; Gerdes J
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():41-9. PubMed ID: 7507748
    [No Abstract]   [Full Text] [Related]  

  • 7. Distinctive biology of pleomorphic lobular carcinoma of the breast.
    Moe RE; Anderson BO
    J Surg Oncol; 2005 May; 90(2):47-50. PubMed ID: 15844193
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
    Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative therapy for elderly patients with breast cancer.
    von Rueden DG; Sessions SC
    Am Surg; 1994 Jan; 60(1):72-8. PubMed ID: 8273979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
    Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
    Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary tumour.
    Martins A; Serrão V; Fiadeiro T; Lopes MP; Campos F; Pereira H; Rodrigues JC
    Histopathology; 2008 Apr; 52(5):654-5. PubMed ID: 18312349
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobular carcinoma in situ of the breast: results of a radiosurgical conservative treatment.
    Cutuli B; Jaeck D; Renaud R; Rodier JF
    Oncol Rep; 1998; 5(6):1531-3. PubMed ID: 9769400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR imaging features of invasive breast cancer correlated with hormonal receptors: does progesterone receptor matter?
    Chen JH; Nalcioglu O; Su MY
    Ann Oncol; 2008 May; 19(5):1024-6. PubMed ID: 18375524
    [No Abstract]   [Full Text] [Related]  

  • 15. Receptors for estrogen and progesterone in breast carcinoma in situ.
    Pallis L; Wilking N; Cedermark B; Rutqvist LE; Skoog L
    Anticancer Res; 1992; 12(6B):2113-5. PubMed ID: 1295456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and morphological features and treatment for lobular breast cancer].
    Tabagua TT; Semiglazov VV; Bus'ko EA; Semiglazova TIu; Voroshnikov VV
    Vopr Onkol; 2013; 59(3):386-9. PubMed ID: 23909043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
    Osin P; Crook T; Powles T; Peto J; Gusterson B
    Lancet; 1998 May; 351(9114):1487. PubMed ID: 9605807
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 19. Biological staging of incipient, in situ, and invasive breast carcinomas.
    Querzoli P; Albonico G; Ferretti S; Rinaldi R; Nenci I
    Ann N Y Acad Sci; 1996 Apr; 784():381-94. PubMed ID: 8651586
    [No Abstract]   [Full Text] [Related]  

  • 20. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
    Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
    J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.